Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

486

Participants

Timeline

Start Date

January 25, 2019

Primary Completion Date

May 21, 2022

Study Completion Date

May 21, 2022

Conditions
Asthma
Interventions
DRUG

Dupilumab SAR231893

"Pharmaceutical form: Solution~Route of administration: Subcutaneous"

DRUG

Placebo

"Pharmaceutical form: Solution~Route of administration: Subcutaneous"

DRUG

Asthma Controller Therapies (include prednisone/prednisolone)

"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"

DRUG

Asthma Reliever Therapies

"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"

Trial Locations (67)

100020

Investigational Site Number :1560016, Beijing

100029

Investigational Site Number :1560029, Beijing

100034

Investigational Site Number :1560015, Beijing

110001

Investigational Site Number :1560018, Shenyang

110004

Investigational Site Number :1560036, Shenyang

110060

Investigational Site Number :3560001, New Delhi

130041

Investigational Site Number :1560057, Changchun

160012

Investigational Site Number :3560006, Chandigarh

160062

Investigational Site Number :3560012, Mohali

200025

Investigational Site Number :1560050, Shanghai

200030

Investigational Site Number :1560049, Shanghai

200032

Investigational Site Number :1560005, Shanghai

200080

Investigational Site Number :1560011, Shanghai

200120

Investigational Site Number :1560017, Shanghai

200233

Investigational Site Number :1560006, Shanghai

200433

Investigational Site Number :1560002, Shanghai

210005

Investigational Site Number :1560051, Nanjing

210006

Investigational Site Number :1560054, Nanjing

210029

Investigational Site Number :1560037, Nanjing

215006

Investigational Site Number :1560031, Suzhou

221002

Investigational Site Number :1560023, Xuzhou

225001

Investigational Site Number :1560055, Yangzhou

300052

Investigational Site Number :1560020, Tianjin

302023

Investigational Site Number :3560005, Jaipur

302039

Investigational Site Number :3560015, Jaipur

310003

Investigational Site Number :1560019, Hangzhou

310006

Investigational Site Number :1560007, Hangzhou

310009

Investigational Site Number :1560014, Hangzhou

310016

Investigational Site Number :1560026, Hangzhou

325000

Investigational Site Number :1560021, Wenzhou

330006

Investigational Site Number :1560024, Nanchang

337055

Investigational Site Number :1560035, Pingxiang

361004

Investigational Site Number :1560046, Xiamen

400038

Investigational Site Number :1560025, Chongqing

410013

Investigational Site Number :1560010, Changsha

411001

Investigational Site Number :3560009, Pune

430000

Investigational Site Number :1560052, Wuhan

430030

Investigational Site Number :1560028, Wuhan

440012

Investigational Site Number :3560003, Nagpur

Investigational Site Number :3560016, Nagpur

500082

Investigational Site Number :3560013, Hyderabad

510080

Investigational Site Number :1560004, Guangzhou

510120

Investigational Site Number :1560001, Guangzhou

510150

Investigational Site Number :1560045, Guangzhou

518020

Investigational Site Number :1560012, Shenzhen

518102

Investigational Site Number :1560042, Shenzhen

524001

Investigational Site Number :1560047, Zhanjiang

550002

Investigational Site Number :1560032, Guiyang

610041

Investigational Site Number :1560030, Chengdu

632004

Investigational Site Number :3560007, Vellore

641028

Investigational Site Number :3560002, Coimbatore

673008

Investigational Site Number :3560011, Kozhikode

700107

Investigational Site Number :3560010, Kolkata

730000

Investigational Site Number :1560022, Lanzhou

830054

Investigational Site Number :1560033, Ürümqi

014010

Investigational Site Number :1560013, Baotou

Unknown

Investigational Site Number :1560056, Beijing

Investigational Site Number :1560053, Chengdu

Investigational Site Number :1560043, Hangzhou

Investigational Site Number :1560038, Hefei

Investigational Site Number :1560040, Xi'an

Investigational Site Number :1560027, Xiangtan

010017

Investigational Site Number :1560044, Hohhot

010050

Investigational Site Number :1560008, Hohhot

050000

Investigational Site Number :1560003, Shijiazhuang

050041

Investigational Site Number :1560041, Shijiazhuang

030001

Investigational Site Number :1560048, Taiyuan

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY